The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis

Journal of Pathology

Volumn 220, Issue 1, 2010, Pages 5-6

  Herrington, C Simon ^a   McCluggage, W Glenn ^b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Carcinoma; Fallopian tube; Ovary; p53; Pelvis; Serous

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; PROTEIN P53;

CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; FAMILIAL CANCER; GENE FREQUENCY; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MUTATION; NOTE; OVARY; OVARY CARCINOMA; PELVIC SEROUS CARCINOMA; PELVIS CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RARE DISEASE; RISK REDUCTION; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE; TUMOR LOCALIZATION; UTERINE TUBE; UTERINE TUBE CARCINOMA; WILD TYPE;

CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, P53; HUMANS; LI-FRAUMENI SYNDROME; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73649107646     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2630     Document Type: Note

References (15)

1. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004;23:200-205.
2. Shih I-M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518.
3. Vang R, Shih I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anatomic Pathol 2009;16:267-282.
4. Russell SE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004;203:617-619.
5. Hudson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995;27:367-371.
6. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anatomic Pathol 2006;13:1-7.
7. Kindelberger D, Lee Y, Miron A, Hirsch M, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161- 169.
8. Lee Y, Miron A, Drapkin R, Nucci M, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal Fallopian tube. J Pathol 2007;211:26-35.
9. Folkins A, Jarboe E, Saleemuddin A, Lee Y, Callahan M, Drapkin R, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and Fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008;109:168-173.
10. Jarboe E, Folkins A, Nucci M, Kindelberger D, Drapkin R, Miron A, et al. Serous carcinogenesis in the Fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008;27:1-9.
11. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008;53:127-138.
12. Xian W, Miron A, Roh M, Semmel DR, Yassin Y, Garber J, et al. The Li Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol 2009;DOI: 10.1002/path.2624.
13. Hes FJ, Morreau H. Where genetics and pathology meet: mulibrey nanism. J Pathol 2009;218:143-145.
14. Jarboe EA, Pizer ES, Miron A, Monte N, Mutter GL, Crum CP. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol 2009;22:345-350.
15. Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 2009;33:376-383.